References
- FK-906. Drugs of the future 1993; 18: 312–315, Anon.
- Hashimoto N., Fujioka T., Hayashi K., Odaguchi K., Toyoda T., Nakamura M., Hirano K. Renin inhibitor: relation between molecular structure and oral absorption. Pharmaceutical Research 1994; 11: 1443–1447
- Hjártstam J., Borg K., Linstedt. The effect of tensile stress on permeability of free films of ethyl cellulose containing hydroxypropyl methylcellulose. International Journal of Pharmaceutics 1990; 61: 101–107
- Jang J.-W., Kitamura S., Guillory J. K. Some physicochemical properties of FK906; glass transition and relaxation. PDA Journal of Pharmaceutical Science and Technology 1995; 49: 42–49
- John P. M., Minatoya H., Rosenberg F. J. Microencapsulation of biloterol for controlled release and its effect on bronchodilator and heart rate activities in dogs. Journal of Pharmaceutical Sciences 1979; 68: 475–480
- Karajiannis H., van de Waterbeemd H. The prediction of the lipophilicity of peptidomimetics. A comparison between experimental and theoretical lipophilicity values of renin inhibitors and their building blocks. Pharmaceutica Acta Helvetiae 1995; 70: 67–77
- Koida Y., Kobayashi M., Samejihia M. Studies on microcapcules. IV. Influence of properties of drugs on microencapsulation and dissolution behavior. Chemical and Pharmaceutical Bulletin 1986; 34: 3354–3361
- Powell T. C. Wall sealing treatment for minute capsules and minute capsules having walls of sealed polymeric material. US Patent 3,623,997, 1971, The National Cash Register Company
- Ragnarsson G., Sandberg A., Johansson M. O., Linsrem B., Sjögren J. In oitro release characteristics of a membrane-coated pellet formulation—influence of drug solubility and particle size. International Journal of Pharmaceutics 1992; 79: 223–232
- Thohla K., Zimmer T. Retardation of weakly basic drugs. 1st communication: Improvement of availability-problems with noscapine in diffusion-pellets. Pharmazeutische Industrie 1989; 51: 98–101
- Thoma K., Zimmer T. Retardation of weakly basic drugs. 2nd communication: optimization of availability with papaverine and codeine in diffusion-pellets. Pharmazeutische Industrie 1989; 51: 540–543
- Thoma K., Knott F. Retardation of weakly basic drugs. 4th communication: solving the availability problems of vincamine from diffusion dosage forms. Pharmazeutische Industrie 1991; 53: 595–600